Vesugen: research

An experimental blood-vessel peptide with unclear benefits and poorly defined safety.

Also called: Vezugen, KED, Lys-Glu-Asp, T-38.

Khavinson bioregulator peptides · Synthetic vascular tripeptide.

12 clinical papers and 2 patent examples found. Reports may include the same participants; these are not 14 independent trials.

Studies

• Truck drivers and stress. cohort, n=300, 150 male truck drivers and 150 male metal workers.. Combined Pinealon and Vesugen had the strongest reported changes in stress-related questionnaire scores. (source)
• Blood flow after leg-artery surgery. cohort, n=41, 41 patients after surgery for chronic lower-limb arterial insufficiency.. Authors reported better clinical and ultrasound measures after Vesugen. (source)
• Vascular report with conflicting indexing. cohort, n=41, 41 people; title describes leg disease, while the abstract describes vascular erectile dysfunction.. The abstract reports improved penile blood flow; the title and abstract do not match. (source)
• Older adults with several illnesses. cohort, n=32, Reported n=32, ages 41-83, with chronic illnesses and brain disorders in remission.. Aging-marker changes came with prooxidant activity and fewer circulating CD34+ cells. (source)
• Work-ability index report. cohort, Workers exposed to occupational hazards; sample size unavailable in the abstract.. Combined cytogens reportedly improved work-ability measures; Vesugen-specific effects cannot be isolated. (source)
• Comparison of aging interventions. cohort, n=110, 110 people in several age groups.. Vesugen plus Pinealon had the strongest reported changes in biological-age indicators. (source)
• Mouth inflammation after cancer therapy. cohort, n=22, 22 older adults after combined therapy for oropharyngeal cancer.. A regimen containing Vesugen and another supplement reportedly improved oral recovery. (source)
• Dry mouth after chemotherapy. cohort, n=27, 27 patients aged 61-75 after cancer chemotherapy, plus 13 healthy reference participants.. A multicomponent regimen improved saliva measures; it cannot establish Vesugen benefit alone. (source)
• Chronic salivary-gland inflammation. cohort, n=36, 36 adults aged 61-81 with a flare of chronic nonspecific salivary-gland inflammation.. Combination care reduced symptoms faster; the peptide contribution is unknown. (source)
• Dry mouth after radiation. cohort, Older patients with salivary-gland damage after oropharyngeal cancer therapy.. A regimen including Vesugen was reported to improve salivary function. (source)
• Salivary-gland disease in older adults. cohort, Hospitalized older adults with Mikulicz disease or Sjogren syndrome.. Exercise, massage and a multicomponent regimen including Vesugen reportedly improved symptoms. (source)
• Salivary disease, stress and sleep. cohort, n=69, 69 adults aged 61-85: cancer n=21, reactive disease n=16, drug/radiation injury n=32.. Adding an anxiety medicine, rather than Vesugen alone, was linked to better stress and sleep measures. (source)
• Patent only: capillary fragility. case-series, Adults aged 19-35 with signs of vitamin deficiency.. The patent claims fewer petechiae after injections; enrollment counts conflict. (source)
• Patent only: age-related purpura. case-series, n=23, 23 adults aged 70-82 with age-related purpura.. The patent claims improved capillary and clotting measures. (source)
• Identity and cell differentiation. in-vitro, Aging human cell cultures.. Vesugen was identified as Lys-Glu-Asp and changed differentiation markers in fibroblasts. (source)
• Vascular cells and Ki-67. in-vitro, Cultured vascular cells from young and old animals; computer docking.. Vesugen increased Ki-67; docking proposed an interaction near its gene promoter. (source)
• Vascular cell renewal. in-vitro, Organ and dissociated vascular cell cultures.. T-38 increased Ki-67 and reduced p53 and E-selectin expression. (source)
• Atherosclerosis and restenosis models. in-vitro, Cultured vascular endothelium under disease-model conditions.. KED changed endothelin-1, connexins and SIRT1 expression in cells. (source)
• Stem-cell aging signals. in-vitro, Human embryonic bone-marrow stem cells aged in culture.. Short peptides including KED altered IGF1, FOXO1 and other aging-related genes. (source)
• Neurons made from donor skin cells. in-vitro, Induced neurons made from older human donors' fibroblasts.. KED promoted dendrite branching; it did not improve mitochondrial, lysosomal or p16 measures. (source)
• Cyclophosphamide and spleen tissue. in-vitro, Rat spleen tissue explants exposed to cyclophosphamide.. T-38 reduced the growth-suppressing effect of cyclophosphamide in cultured tissue. (source)
• Short peptides under low oxygen. animal, Animal low-oxygen models.. Several peptides showed activity; Pinealon had the strongest reported effect. (source)
• KED in an Alzheimer mouse model. animal, 5xFAD-M mice and control mice.. KED changed spine shape; total spine density did not significantly change. (source)

Gaps: No registered human trial, reliable pharmacokinetic study or dose-finding program was found. No human subcutaneous or intranasal studied maximum is known; oral and patent IM amounts cannot supply one. Human reports often omit doses, arm counts, adverse-event rates or numerical outcomes. Several cohorts may overlap. The 2014 vascular record has a title/abstract mismatch. An inaccessible 2016 conference report mentions 59 patients; overlap and full methods need checking. A 2005-2006 developer report is distributed through sellers; independent primary verification was not obtained. Long-term cancer, reproductive, immune and organ safety remain unknown. No verified microdosing ladder or validated storage instructions were found.

Related to Vesugen

• Epitalon: A peptide with telomerase effects in cells, but no proof that people live longer.
• Pinealon: A peptide with unproven brain benefits and no established injection dose.
• Thymalin: A calf thymus extract studied for immune problems, with uncertain safety and product identity.
• Thymogen: A Russian peptide used for immune problems, with negative cancer trials.
• Cortagen: A four-amino-acid brain peptide backed mainly by animal work and unverified patent claims.
• BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.

Vesugen: the short version

Sources

• 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
• 503B Bulk Drug Substances List, FDA · FDA · 2026
• Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, US Food and Drug Administration · 2026
• Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
• Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
• Medicines, European Medicines Agency · European Medicines Agency · 2026
• The Prohibited List, World Anti-Doping Agency · World Anti-Doping Agency · 2026
• Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
• Understanding your responsibilities when importing, compounding and supplying unapproved peptide products, Therapeutic Goods Administration · Therapeutic Goods Administration · 2026
• Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
• Anaphylaxis, National Library of Medicine
• Drugs@FDA: FDA-Approved Drugs, US Food and Drug Administration
• Heart Attack, National Library of Medicine
• Sepsis, National Library of Medicine
• Stroke, National Library of Medicine

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.